Strategic Partnerships DiaSorin’s ongoing collaborations with McKesson, Thermo Fisher Scientific, QIAGEN, and Inpeco indicate a strong channel-focused growth strategy. A sales approach that offers integrated, automated immunodiagnostic workflows and point-of-care capabilities to these distribution and automation partners could expand market reach and accelerate adoption in health systems.

Automation & Precision The company emphasizes partnering science and automation to simplify specialty testing, with a focus on precision medicine, companion diagnostics, and automate-ready LIAISON platforms. Target opportunities include labs seeking end-to-end automation, high-throughput throughput immunodiagnostics, and integrated QA/QC across clinical laboratories.

Infectious Disease Focus Recent launches and CE-marked assays for infectious diseases such as TB, C. auris, Flu A/B, RSV, and SARS-CoV-2 position DiaSorin to pursue hospitals and labs expanding infectious disease panels, multiplex testing, and rapid molecular diagnostics within inpatient and reference lab networks.

Global Expansion Leadership additions in precision medicine and global immunodiagnostics, along with international partnerships, point to potential sales opportunities in multinational health systems and emerging markets that require validated companion diagnostics, robust automation, and cross-border support.

Growth Signals Frequent press coverage of leadership hires, product launches, and strategic partnerships suggests a growth trajectory. This creates cross-sell and upsell opportunities for existing customers of related immunodiagnostic and automation platforms, as well as the chance to introduce newer rapid and point-of-care assays via distribution networks.